A PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION FOR MALIGNANT-LYMPHOMA

被引：23

作者：

PRZEPIORKA, D ^{[1
]}

NATH, R ^{[1
]}

IPPOLITI, C ^{[1
]}

MEHRA, R ^{[1
]}

HAGEMEISTER, F ^{[1
]}

DIENER, K ^{[1
]}

DIMOPOULOS, M ^{[1
]}

GIRALT, S ^{[1
]}

KHOURI, I ^{[1
]}

SAMUELS, B ^{[1
]}

VANBESIEN, K ^{[1
]}

ANDERSSON, B ^{[1
]}

DEISSEROTH, AB ^{[1
]}

LUNA, M ^{[1
]}

CABANILLAS, F ^{[1
]}

CHAMPLIN, R ^{[1
]}

机构：

[1] UNIV TEXAS,MD ANDERSON CANC CTR,BONE MARROW TRANSPLANTAT SECT,HOUSTON,TX

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 17卷 / 5-6期

关键词：

AUTOLOGOUS MARROW TRANSPLANTATION; LYMPHOMA; THIOTEPA; BUSULFAN; CYCLOPHOSPHAMIDE;

D O I：

10.3109/10428199509056853

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support. Four patients were in untreated relapse, 7 had stable or progressive disease, 12 were in partial remission, and Il were in complete remission after reinduction chemotherapy before proceeding to the preparative regimen. Median follow-up time is 22 months. Grades 3-4 regimen-related toxicity occurred in 3 (14%) of 22 patients treated with THIO 250 mg/m(2) x 3, BU 1 mg/kg x 10 and CYC 50 mg/kg x 3, and this was considered the maximal tolerated dose-schedule. Of the 23 patients with active disease at the time of transplantation, 52% (95% CI31-73%) achieved a complete response, and 26% (95% CI 10-48%) achieved a partial response. For all patients, median time to progression was 13 months, median survival was 16 months, and disease-free survival at 18 months was 34% (95% CI 18-51%). The combination of THIO, BU and CYC is tolerable as a preparative regimen for lymphoma and has a high response rate, but further measures are needed to reduce the relapse rate for patients with advanced disease.

引用

页码：427 / 433

页数：7

共 33 条

[1] Philip T., Armitage J.O., Spitzer G., Chauvin F., Jagannath S., Cahn J.-Y., Colombat P., Goldstone A.H., Gorin N.C., Flesh M., Laporte J.-P., Maraninchi D., Pico J., Bosley A., Anderson C., Schots R., Biron P., Cabanillas F., Dicke K., High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma, N. Eng. J. Med., 316, pp. 1493-1498, (1987)
[2] Takvorian T., Canellos G.P., Ritz J., Freedman A.S., Anderson K.C., Mauch P., Tarbell N., Coral F., Daley H., Yeap B., Schlossman S.F., Nadler L.M., Prolonged disease-free survival after autologous marow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis, N. Eng. J. Med., 316, pp. 1499-1505, (1987)
[3] Gribben J.G., Goldstone A.H., Linch D.C., Taghipour G., McMillan A.K., Souhami R.L., Earl H., Richards J.D.M., Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy, J Clin. Oncol., 7, pp. 1621-1629, (1989)
[4] Phillips G.L., Fay J.W., Herzig R.H., Lazarus H.M., Wolff S.N., Lin H.-S., Shina D.C., Glasgow G.P., Griffith R.C., Lamb C.W., Herzig G.P., The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation, Blood., 75, pp. 831-838, (1990)
[5] Petersen F.B., Appelbaum F.R., Hill R., Fisher L.D., Bigelow C.L., Sanders J.E., Sullivan K.M., Bensinger W.I., Witherspoon R.P., Storb R., Clift R.A., Fefer A., Press O.W., Weiden P.L., Singer J., Thomas E.D., Buckner C.D., Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle, J. Clin. Oncol., 8, pp. 638-647, (1990)
[6] Chopra R., Goldstone A.H., Pearce R., Philip T., Petersen F., Appelbaum F., De Vol E., Ernst P., Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European bone marrow transplant group registry data, J. Clin. Oncol., 10, pp. 1690-1695, (1992)
[7] Wheeler C., Strawderman M., Ayash L., Hallowell C., Bierer B.E., Elias A., Gilliland D.G., Antman K., Guinan, Eder E.C., J P., Weinstein H., Schwartz G., Ferrara J., Mazanet R., Rimm I.J., Tepler I., McCarthy P., Mauch P., Ault A., Gaynes L., McCauley M., Schnipper L.E., Antin J., Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide, J. Clin. Oncol., 11, pp. 1085-1091, (1993)
[8] Freedman A.S., Takvorian T., Anderson K.C., Mauch P., Rabinowe S.N., Blake K., Yeap B., Soiffer R., Coral F., Heflin L., Ritz J., Nadler L.M., Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse, J. Clin. Oncol., 8, pp. 784-791, (1990)
[9] Gulati S., Yahalom J., Acaba L., Reich L., Motzer R., Crown J., Toia M., Lgarashi T., Lemoli R., Hanninen E., Doherty M., Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation, J. Clin. Oncol., 10, pp. 936-941, (1992)
[10] Bearman S.I., Appelbaum F.R., Back A., Petersen F.B., Buckner C.D., Sullivan K.M., Schoch H.G., Fisher L.D., Thomas E.D., Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma, J. Clin. Oncol, 1, pp. 1288-1294, (1989)

← 1 2 3 4 →